@article{ba9989fca8c847dbb957b50e92a2f905,
title = "Clinical Use of Clozapine Serum Level and Management of Adverse Effects in an Adolescent with Difficult to Treat Schizophrenia",
author = "Yasin Bez and Sindhura Kompella and Felicia Gallucci and Adam Awerbuch and Coffey, {Barbara J.}",
note = "Funding Information: B.J.C. is on the scientific advisory board of Teva/Nuvelution, received honoraria from the American Academy of Child and Adolescent Psychiatry, Partners Healthcare, Harvard Medical School/Psychiatry Academy, grant support from Florida Children{\textquoteright}s Medical Services, and research support from Teva/Nuvelution, Emalex, and National Institute of Mental Health. She is on the national advisory board of Skyland Trail, is cochair of the medical advisory board of the Tourette Association of America (TAA), a nonpaid position, and on the speakers{\textquoteright} bureau for the TAA–Centers for Disease Control and Prevention partnership. Y.B., F.G, A.A., and S.K. have no disclosures.",
year = "2021",
month = dec,
day = "1",
doi = "10.1089/cap.2021.29213.bjc",
language = "English (US)",
volume = "31",
pages = "699--703",
journal = "Journal of Child and Adolescent Psychopharmacology",
issn = "1044-5463",
publisher = "Mary Ann Liebert Inc.",
number = "10",
}